News

PSMA-Targeting Therapy Shows Promise, Precision in Patients With mCRPC

07/26/2021

177Lu-PSMA-617 met both primary end points and substantially improved OS and PFS outcomes in patients with PSMA+ mCRPC, according to the phase 3 VISION study.

177Lu-PSMA-617 met both primary...

07/26/2021

Oncology

News

Phase I Study of PSMA Targeted 225Ac-J591 Reveals Tolerability in mCRPC

07/13/2021

225Ac-J591 receives first human study with research in PSMA targeting and dose expansion capabilities during an ongoing phase I trial.

225Ac-J591 receives first human...

07/13/2021

Oncology

News

MRSI Parameters Can Predict Early Recurrence Postsurgery in Prostate Cancer

11/25/2019

A study of patients with nonmetastatic prostate cancer suggests that MRSI parameters can predict risk for biochemical recurrence after radical prostatectomy.

A study of patients with...

11/25/2019

Oncology

News

Cabazitaxel Improves Outcomes in Metastatic CRPC Compared With Abiraterone or Enzalutamide

10/29/2019

In a randomized trial, cabazitaxel significantly improved clinical outcomes in certain patients with metastatic CRPC.

In a randomized trial,...

10/29/2019

Oncology

News

Docetaxel Added to Hormone Therapy Benefits Survival in Metastatic Hormone-Sensitive Prostate Cancer

09/28/2019

Long-term follow-up demonstrates a persistent benefit in survival with docetaxel for patients with metastatic hormone-naïve prostate cancer.

Long-term follow-up demonstrates...

09/28/2019

Oncology

News

Apalutamide Reduces Risk of Death in Patients With Nonmetastatic CRPC

09/27/2019

Results from a second interim analysis of the phase 3 SPARTAN study show apalutamide is tied to a 25% reduction in risk for death versus placebo in nonmetastatic CRPC.

Results from a second interim...

09/27/2019

Oncology

News

FDA Approves Apalutamide for Type of Prostate Cancer

09/18/2019

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

The FDA has approved apalutamide...

09/18/2019

Oncology

News

Enzalutamide Tied to Longer OS, PFS Than Standard Care in Hormone-Sensitive Prostate Cancer

09/03/2019

In patients with metastatic, hormone-sensitive prostate cancer undergoing testosterone suppression, enzalutamide was tied to significantly longer PFS and OS than standard care.

In patients with metastatic,...

09/03/2019

Oncology

News

Enzalutamide Plus ADT Reduces Death Risk in Hormone-Sensitive Prostate Cancer

08/12/2019

Enzalutamide combined with ADT significantly reduced the risk for metastatic progression or death in men with metastatic hormone-sensitive prostate cancer.

Enzalutamide combined with ADT...

08/12/2019

Oncology

News

FDA Approves Darolutamide for Nonmetastatic CRPC

07/31/2019

The FDA has approved darolutamide for the treatment of patients with nonmetastatic CRPC.

The FDA has approved...

07/31/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology